Novel simultaneous combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: The power-pulse spray technique

Catheterization and Cardiovascular Interventions

Volumn 63, Issue 4, 2004, Pages 512-522

  Allie, David E ^a,b,e   Hebert, Chris J ^a,b   Lirtzman, Mitchell D ^e   Wyatt, Charles H ^a,b   Keller, V Antoine ^a,c   Khan, Mohamed H ^e   Barker, Esmond A ^a,b   McElderry, Michael W ^a,b   Khan, Muhammad A ^a,b   Fail, Peter S ^a,d   Stagg III, Samuel J ^a,d   Mitran, Elena V ^a   Chaisson, Gary ^a,d   Allie, Sonja D ^a   Allie, Adam A ^a   Walker, Craig M ^a,b,d  

^a Cardiovasc Inst of South Opelousas   (United States)

^b Southwest Medical Center   (United States)

^c Opelousas General Hospital   (United States)

^d Terrebonne General Medical Center   (United States)

^e NONE

Author keywords

Catheterization; Iliac; Percutaneous transluminal angioplasty; Stent; Superficial femoral procedure; Vascular interventions

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HIRULOG; SODIUM CHLORIDE; TENECTEPLASE; TIROFIBAN; UROKINASE;

ADULT; AGED; ARTICLE; BLEEDING; CATHETER; CATHETERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTERVENTIONAL RADIOLOGY; LEG THROMBOSIS; LIMB ISCHEMIA; LIMB SALVAGE; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; POWER PULSE SPRAY TECHNIQUE; RHEOLYTIC THROMBECTOMY; SAFETY; SIDE EFFECT; TECHNIQUE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ARTERIAL OCCLUSIVE DISEASES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL VEIN; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; ILIAC ARTERY; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATORS; POPLITEAL ARTERY; RETROSPECTIVE STUDIES; THROMBECTOMY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 9644303316     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20216     Document Type: Article

References (35)

1. Yeager RA, Moneta GL, Taylor LM, et al. Surgical management of severe acute lower extremity ischemia. J Vasc Surg 1992;15:382-391.
2. Baisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978;84:822-834.
3. Ouriel K, Veith FJ, Sarahara AA, for the Thrombolysis or Arterial Surgery (TOPAS) investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111.
4. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021-1030.
5. Ouriel K. Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. J Vasc Interv Radiol 1995;6:48S-54S.
6. Ouriel K, Shortell CK, Azodo MVU, Guiterrez OH, Marder VJ. Acute peripheral vascular occlusion: predictors of success in catheter-directed thrombolytic therapy. Radiology 1994;193:561-566.
7. Semba CP, Murphy TP, Bakal CW. Thrombolytic therapy with use of alteplase(rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. J Vasc Interv Radiol 2000;11:149-161.
8. Refino CJ, Paoni NF, Keyt BA, et al. A variant of t-PA T103N, KHRR296-299 AAAA that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70:313-319.
9. ASSENT-2 trial. Assessment of the safety and efficacy of a new thrombolytic investigators (ASSENT-2): single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. Lancet 1999;354:716-722.
10. Keyt B, Paoni NF, Refino CJ, et al. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
11. Colleen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in dog. Thromb Haemost 1994;72:98-104.
12. Semba CP, Sugimoto K, Razavi MK. Alteplase and tenecteplase: applications in the peripheral circulation. Tech Vasc Interv Radiol 2001;4:99-106.
13. Ansel GM, George BS, Botti CF, McNamara TO, Jenkins JS, Ramee SR, Rosenfield K, Noethen AA, Mehta T. Rheolytic thrombectomy in the management of limb ischemia: 30 day results from a multicenter registry. J Endovasc Ther 2002;9:395-402.
14. Kasirajan K, Gray B, Beavers F, Clair D, Greenberg R, Mascha E, Ouriel K. Rheolytic thrombectomy in the management of acute and subacute limb-threatening ischemia. J Vasc Interv Radiol 2001;12:413-421.
15. Kasirajan K, Ouriel K. Management of acute lower extremity ischemia: treatment strategies and outcome. Curr Interv Cardiol Rep 2000;2:119-129.
16. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA risk: angioscopy as a clinical tool. Circulation 1996;93:253-258.
17. Meyerovitz M, Goldhaber SZ, Reagan K, et al. Recombined tissue-type plasminogen activator versus Urokinase in peripheral arterial graft occlusion: a randomized trial. Radiology 1990;175:75-78.
18. STILE trial. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Ann Surg 1994;220:251-266.
19. Kandarpa K, Goldhaber SZ, Meyerovitz MF. Pulse spray thrombolysis: the "careful analysis." Radiology 1994;193:320-324.
20. Yusuf SW, Whitaker SC, Gregson RHS, et al. Immediate and early follow-up results of pulse spray thrombolysis in patients with peripheral ischemia. Br J Surg 1995;82:338-340.
21. Armon MP, Yusuf SW, Whitaker SC, Gregson RH, Wenham PW, Hopkinson BR. Results of 100 cases of pulse spray thrombolysis for acute and subacute leg ischemia. Br J Surg 1997;84:47-50.
22. Ouriel K. Thrombolytic solutions for peripheral vascular disease. Rev Cardiovasc Med 2002;3:17-24.
23. Douek PC, Gandjbakhche A, Leon MB, Bonner RF. Functional properties of a prototype rheolytic catheter for percutaneous thrombectomy. Invest Radiol 1994;29:547-552.
24. Müller-Hülsbeck S, Kalinowski M, Heller M, Wagner HJ. Rheolytic hydrodynamic thrombectomy for percutaneous treatment of acutely occluded infra-aortic native arteries and bypass grafts. Invest Radiol 2000;35:131-140.
25. Silva JA, Ramee SR, Collins TJ, Jenkins JS. Rheolytic thrombectomy in the treatment of acute limb threatening ischemia: immediate result and six-month follow-up of the multicenter AngioJet registry. Cathet Cardiovasc Diagn 1998;45:386-393.
26. Reekers JA, Kromhout JG, Spithoven HG, Jacobs MJHM, Mali WMPH, Schultze-Kool LJ. Arterial thrombosis below the inguinal ligament: percutaneous treatment with a thrombosuction catheter. Radiology 1996;198:49-53.
27. Semba S, Week S, Razavi M, Patapoff T. Alteplase stability after thrombolysis-facilitated rheolytic or high-speed maceration thrombectomy. J Vasc Interv Radiol 2002;13:576.
28. Wagner HJ, Müller-Hülsbeck S, Pitton MB, Weiss W, Wess M. Rapid thrombectomy with a hydrodynamic catheter: results from a prospective, multicenter trial. Radiology 1997;205:675-681.
29. Topol E, Califf R, Van de Werf F, et al. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrolytic therapy and platelet glycoprotein Hb/IIIa inhibition: the Gusto V randomized trial. Lancet 2001;357:1905-1914.
30. Rocha-Singh KJ, Trokey J. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis. Catheter Cardiovasc Interv 2002;55:457-460.
31. Leon MB, Bain DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting: Stent Restenosis Study investigators. N Engl J Med 1998;339:1665-1671.
32. Ambrose JA, et al., for the TAUSA investigators. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: results of the TAUSA trial. Circulation 1994;90:69-77.
33. Almeda, FQ, Chua DY, Nathan S, Kim S, et al. Clinical outcomes of patients treated with cutting balloon and Sr-90 beta-irradaiation for instent restenosis. Cardiovasc Radiat Med 2002;3:12-15.
34. Neumann FJ, et al. Effects of glycoprotein IIb/IIIa receptor blockage on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
35. Allie DE, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invas Cardiol 2003;15:334-342.